

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Cardboard box}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Flunex 50 mg/ml solution for injection for cattle, pigs and horses

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Flunixin 50.0 mg

(Equivalent to flunixin meglumine 82.9 mg)

3. PACKAGE SIZE

50 ml

100 ml

250 ml

4. TARGET SPECIES

Cattle, pigs and horses

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Solution for injection

7. WITHDRAWAL PERIODS

Withdrawal period:

Cattle:

Meat and offal: 5 days

Milk: 24 hours

Pigs:

Meat and offal: 22 days

Horses:

Meat and offal: 7 days

Milk: Not authorised for use in animals producing milk for human consumption.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached, use by...

9. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Industrial Veterinaria SA

14. MARKETING AUTHORISATION NUMBERS

Vm 36547/5001

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE {Glass vial}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Flunex 50 mg/ml solution for injection for cattle, pigs and horses

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Flunixin 50.0 mg

(Equivalent to flunixin meglumine 82.9 mg)

3. TARGET SPECIES

Cattle, pigs and horses

4. ROUTES OF ADMINISTRATION

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal periods:

Cattle:

Meat and offal: 5 days

Milk: 24 hours

Pigs:

Meat and offal: 22 days

Horses:

Meat and offal: 7 days

Milk: Not authorised for use in animals producing milk for human consumption.

6. EXPIRY DATE

Exp. {mm/yyyy}

Once broached, use by...

7. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer carton in order to protect from light.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Industrial Veterinaria SA

9. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Flunex 50 mg/ml solution for injection for cattle, pigs and horses

2. Composition

Each ml contains:

Active substance:

Flunixin 50.0 mg
(Equivalent to flunixin meglumine 82.9 mg)

Excipients:

Phenol 5.0 mg

Clear and colourless to light yellow solution, free from visible particles.

3. Target species

Cattle, pigs and horses

4. Indications for use

Cattle:

Reduction of clinical signs during respiratory infections in association with appropriate anti-infective treatment.

Pigs:

Adjunctive therapy of postpartum dysgalactia (Mastitis-metritis-agalactia) syndrome in sows.

Reduction of fever in respiratory diseases in addition to an appropriate antibiotic.

Horses:

Alleviation of inflammation and pain associated with musculoskeletal disorders.

Alleviation of visceral pain associated with colic.

5. Contraindications

Do not use in animals with chronic musculoskeletal disorders.

Do not use in animals with liver, cardiac or renal disease.

Do not use in animals with gastro-intestinal ulceration or bleeding.

Do not use in cases of bleeding disorders.

Do not use in cases of hypersensitivity to the active substance, to other NSAIDs or to any of the excipients.

Do not use in animals suffering from colic caused by ileus and associated with dehydration.

Do not use in cattle within 48 hours before expected parturition in cows.

See section “Use during pregnancy, lactation or lay”.
Do not use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.

6. Special warnings

Special warnings:

Non-steroidal, anti-inflammatory drugs are not permitted under the rules of Racing and under rules covering other competitive events.

The Royal College of Veterinary Surgeons has given advice to the Veterinary Profession regarding the use of anti-inflammatory drugs in competing horses. It states that “if a veterinarian recommends the discontinuation of any such drug not less than eight days before racing, he should feel sure that he has catered for all but the most exceptional case”.

Special precautions for safe use in the target species:

Inject slowly as life-threatening symptoms of shock can occur due to the content of propylene glycol. The product should have a temperature close to body temperature. Stop injection immediately if first symptoms of shock occur and start treatment for shock if necessary.

It is known that non-steroidal anti-inflammatory drugs can potentially delay labour through a tocolytic effect, inhibiting prostaglandins which are important for signalling the onset of labour. The use of the veterinary medicinal product in the period immediately following birth may interfere with uterine involution and the expulsion of the foetal membranes. This can lead to placental retention.

Do not exceed the recommended dose or duration of treatment.

Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.

Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock.

It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.

The cause of colic should be determined and treated with concurrent therapy.

The product should not be used in piglets weighing less than 6 kg.

Ponies may be more sensitive to adverse reactions caused by NSAIDs and therefore the product should be used with caution in these animals. In horses, the cause of colic must be well determined and treated with adequate concomitant therapy.

Avoid intraarterial administration.

Horses to which the veterinary medicinal product is accidentally administered intraarterially may demonstrate ataxia, incoordination, hyperventilation, hysteria, muscle weakness. These are transitory signs that disappear within a few minutes, without the administration of an antidote.

Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to enter wild fauna food chain. In case of death or sacrifice of treated animals, ensure that they are not made available to wild fauna.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The veterinary medicinal product may cause allergic reactions in sensitised individuals.

People with known hypersensitivity to substances belonging to the non-steroidal anti-inflammatory group should avoid contact with the veterinary medicinal product.

Laboratory studies with flunixin have shown evidence of foetotoxic effects in rats.

Pregnant women should use the product with caution to avoid accidental self-injection.

The veterinary medicinal product can cause skin and eye irritation. Avoid contact with the skin and eyes. In the event of skin contact, wash exposed area immediately with soap and water.

In the event of contact with the eyes, rinse immediately with plenty of water.

If skin / eye irritation persists, seek medical advice immediately and show the package leaflet or the label to the physician.

To avoid risk of ingestion, it is recommended not to eat or drink when using the veterinary medicinal product.

In case of accidental self-injection or ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Studies in laboratory animals have produced evidence of foetotoxicity from flunixin after oral administration (rabbit and rat) and intramuscular administration (rat) at maternotoxic doses as well as an increase in the gestation period (rat).

The safety of flunixin has not been assessed in pregnant mares, breeding stallions and bulls. Do not use in these animals.

The safety of flunixin was demonstrated in pregnant cows and sows, as well as boars. The veterinary medicinal product may be used in these animals except within the 48 hours preceding parturition (see sections 3.3 and 3.6).

The veterinary medicinal product should only be administered within the first 36 hours post-partum following a benefit/risk assessment performed by the responsible veterinarian, and treated animals should be monitored for retained placentae.

Interaction with other medicinal products and other forms of interaction:

The concurrent administration of other NSAIDs concurrently or within 24 hours of each other should be avoided, as it may increase the toxicity, mainly gastrointestinal, even with low doses of acetylsalicylic acid.

The concurrent administration of corticoids may increase toxicity of the two products and increase the risk of gastro-intestinal ulceration. It should therefore be avoided.

Flunixin may reduce the effect of some anti-hypertensive medicinal products such as diuretics, Angiotensin Conversion Enzyme (ACE) inhibitors, and beta blockers, by inhibition of prostaglandin synthesis.

The concurrent administration of potentially nephrotoxic drugs, particularly aminoglycosides, should be avoided.

Flunixin may reduce renal elimination of some drugs and increase their toxicity, such as aminoglycosides for example.

Overdose:

Overdosage studies in the target species have shown the product to be well tolerated. Flunixin meglumine is a non-steroidal anti-inflammatory drug.

Overdosage is associated with gastrointestinal toxicity. Concurrent use of nephrotoxic drugs should be avoided.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Cattle, pigs and horses:

| | |
|--|---|
| Undetermined frequency: (cannot be estimated from the available data) | Bleeding Gastrointestinal irritation ¹ Gastrointestinal ulceration ¹ Vomiting ¹ Renal damage ^{1,2} Hepatic damage ^{1,2} Delayed parturition ³ , increase of stillbirths ³ , retained placenta ⁴ |
|--|---|

¹Mainly in dehydrated or hypovolaemic animals

²As with other NSAIDs, rare renal or idiosyncratic hepatic adverse reactions may be observed.

³through a tocolytic effect by inhibiting prostaglandins that are important in signalling the initiation of parturition

⁴in cases of the use of the veterinary medicinal product in the immediate post-partum period

Cattle and horses:

| | |
|---|---|
| Rare (1 to 10 animals / 10,000 animals treated): | Anaphylactic (with collapse) ¹ Death ¹ |
|---|---|

¹mainly during rapid intravenous injection

Cattle:

| | |
|--|--------------------------------------|
| Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Injection site reaction ¹ |
|--|--------------------------------------|

¹after intramuscular administration

Horses:

| | |
|---|---|
| Undetermined frequency (cannot be estimated from the available data) | blood in faeces ¹ , diarrhea (liquid) ¹ |
|---|---|

¹after intravenous injection

In case of untoward effects stop treatment and seek medical advice.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing

authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at <https://www.gov.uk/report-veterinary-medicine-problem>.

8. Dosage for each species, routes and method of administration

For intravenous use in cattle and horses.
For intramuscular use in pigs.

Cattle

2 ml per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) administered intravenously. Repeat as necessary at 24 hour intervals for up to 5 consecutive days.

Pigs

- Postpartum dysgalactia syndrome (Mastitis-metritis-agalactia):
2 ml per 50 kg bodyweight (equivalent to 2 mg flunixin/kg) by intramuscular injection for 1 to 3 consecutive days.
- Reduction of fever in respiratory diseases:
2 ml per 45 kg bodyweight (equivalent to 2.2 mg flunixin/kg) once by intramuscular injection, in the neck, in addition to an appropriate antibiotic. The injection volume should be limited to a maximum of 5 ml per injection site.

Horses

- Alleviation of inflammation and pain associated with musculoskeletal disorders:
1 ml per 45 kg bodyweight (equivalent to 1.1 mg flunixin/kg) by intravenous injection once daily for up to 5 days according to clinical response.
- Alleviation of pain associated with colic:
1 ml per 45 kg bodyweight (equivalent to 1.1 mg flunixin/kg) by intravenous injection. Treatment may be repeated once or twice if colic recurs.
For the treatment of endotoxaemia or septic shock associated with gastric torsion and with other conditions in which the circulation of blood to the gastro-intestinal tract is compromised: 0.25 mg/kg every 6-8 hours, by intravenous injection.

9. Advice on correct administration

To ensure a correct dosage, body weight should be determined as accurately as possible.

The stopper may be safely punctured up to 25 times with a 18 G needle size and up to 100 times with a 21 G needle size. For multiple vial entry, an aspirating needle or multi-dose syringe is recommended to avoid excessive broaching of the stopper.

10. Withdrawal periods

Cattle:

Meat and offal: 5 days
Milk: 24 hours

Pigs:

Meat and offal: 22 days

Horses:

Meat and offal: 7 days

Milk: Not authorised for use in animals producing milk for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions. Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 36547/5001

Cardboard box with 1 vial of 50 ml

Cardboard box with 1 vial of 100 ml

Cardboard box with 1 vial of 250 ml

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:
Industrial Veterinaria SA
Calle Esmeralda, 19
E-08950 Esplugues de Llobregat
Spain

Manufacturer responsible for batch release:
aniMedica Herstellungs GmbH
Im Südfeld 9
48308 Senden-Bösensell
Germany

aniMedica GmbH
Im Südfeld 9
48308 Senden-Bösensell
Germany

Industrial Veterinaria, S.A.
Esmeralda, 19
08950 Esplugues de Llobregat
(Barcelona) Spain

Local representatives and contact details to report suspected adverse reactions:
FORTE Healthcare Limited
Block 3, Unit 9
CityNorth Business Campus
Stamullen, Co. Meath
K32 D990
Republic of Ireland

17. Other information

| | |
|-------|--|
| POM-V | Veterinary medicinal product subject to prescription |
|-------|--|

Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to enter wild fauna food chain. In case of death or sacrifice of treated animals, ensure that they are not made available to wild fauna.

Gavin Hall

Approved: 25 November 2024